CareDx, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

CDNA$84.42+7.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except share and per share data)

	Year Ended December 31,
	2025	2024	2023
Revenue:
Testing services revenue	$274,495	$249,381	$209,685
Product revenue	48,377	40,783	33,517
Patient and digital solutions revenue	56,933	43,621	37,122
Total revenue	379,805	333,785	280,324
Operating expenses:
Cost of testing services	62,045	55,611	57,642
Cost of product	22,953	23,381	18,379
Cost of patient and digital solutions	38,241	30,704	26,045
Research and development	71,429	72,510	82,421
Sales and marketing	102,643	81,975	84,062
General and administrative	107,565	125,139	118,838
Litigation settlement expense	5,710	(96,300)	96,300
Total operating expenses	410,586	293,020	483,687
(Loss) income from operations	(30,781)	40,765	(203,363)
Other income:
Interest income, net	9,174	11,765	11,867
Other income, net	524	329	1,353
Total other income	9,698	12,094	13,220
(Loss) income before income taxes	(21,083)	52,859	(190,143)
Income tax expense	(271)	(310)	(141)
Net (loss) income	$(21,354)	$52,549	$(190,284)
Net (loss) income per share (Note 3):
Basic	$(0.40)	$1.00	$(3.54)
Diluted	$(0.40)	$0.93	$(3.54)
Weighted-average shares used to compute net (loss) income per share:
Basic	53,287,546	52,773,247	53,764,705
Diluted	53,287,546	56,620,590	53,764,705

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.